{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:47:10Z","timestamp":1792392430775,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101104269"],"award-info":[{"award-number":["101104269"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103725","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:00:17Z","timestamp":1767110417000},"page":"103725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-9867","authenticated-orcid":false,"given":"Sahar","family":"Barjesteh van Waalwijk van Doorn-Khosrovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103725_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejca.2021.06.058","article-title":"Nested and adjacent subgroups in cancer clinical trials: when the best interests of companies and patients diverge","volume":"155","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2025.103725_bib2","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.eclinm.2025.103725_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eclinm.2025.103725_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2024.42.4_suppl.165","article-title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103725_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib7","series-title":"FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103725_bib8","series-title":"Assessment report Akeega, Procedure No. EMEA\/H\/C\/005932\/0000","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103725_bib9","series-title":"Assessment report Talzenna, Procedure No. EMEA\/H\/C\/004674\/X\/0015\/G","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103725_bib10","series-title":"Assessment report Lynparza, Procedure No. EMEA\/H\/C\/003726\/II\/0053","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103725_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US food and drug administration approval summary: Talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib12","series-title":"FDA Approves Olaparib with Abiraterone and Prednisone (or prednisolone) for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103725_bib13","series-title":"FDA Briefing Document. NDA 208558\/Supplement 25. Drug name: olaparib (Lynparza)","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103725_bib14","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.23.00270","article-title":"Combining Poly(ADP)-Ribose polymerase inhibitors with abiraterone in castration-resistant prostate cancer: is biomarker testing necessary?","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib16","series-title":"Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry","year":"2018"},{"key":"10.1016\/j.eclinm.2025.103725_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103725_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103725_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib20","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103725_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2024.05.014","article-title":"Testing dilemmas in the clinic: lessons learned from biomarker-based drug development","volume":"42","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eclinm.2025.103725_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.euo.2025.09.016","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA damage response alterations\u2014genomic features associated with response to therapy","volume":"8","author":"Fizazi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eclinm.2025.103725_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod Pathol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:20:43Z","timestamp":1777634443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S2589537025006601"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103725","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103725"}}